Document is current
Any future updates will be listed below
-
Authors
Nash, Amanda
DeBonis, Jonathon https://orcid.org/0009-0004-8965-383X
Murungi, Danna
Castillo, Bertha
Kim, Boram
Hu, Fangheng
Chambers, Courtney
Nguyen, Annie
Hernandez, Andrea
Wang, Zeshi
Rios, Peter D
Ghani, Sofia
Joshi, Ira
Isa, Douglas
Zheng, Ningbo
Peng, Weiyi https://orcid.org/0000-0002-7785-6240
Igoshin, Oleg A
Oberholzer, Jose
Hodges, H Courtney https://orcid.org/0000-0003-4441-497X
Reticker-Flynn, Nathan
Veiseh, Omid https://orcid.org/0000-0003-1153-8079
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05538624 at ClinicalTrials.govnct05538624 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps5616
IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumors
https://doi.org/10.1136/jitc-2024-010685
1045 Overcoming immunosuppressive tumors by stimulating the adaptive and innate immune systems
https://doi.org/10.1136/jitc-2023-sitc2023.1045
nct05538624 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps5616
IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumors
https://doi.org/10.1136/jitc-2024-010685
1045 Overcoming immunosuppressive tumors by stimulating the adaptive and innate immune systems
https://doi.org/10.1136/jitc-2023-sitc2023.1045
Documents that mention this clinical trial
A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps5616
IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumors
https://doi.org/10.1136/jitc-2024-010685
1045 Overcoming immunosuppressive tumors by stimulating the adaptive and innate immune systems
https://doi.org/10.1136/jitc-2023-sitc2023.1045
-
Funding
Funding for this research was provided by:
Cancer Prevention Research Institute of Texas (RR160047)
Advanced Research Projects Agency for Health (AY1AX000003)
Center for Cancer Research (R01CA272769)
Common Fund (AI177915)
SRA
- License Information
